#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer


Autoři: Wan-Yu Chen aff001;  Tseng-Cheng Chen aff004;  Shih-Fan Lai aff001;  Tony Hsiang-Kuang Liang aff001;  Bing-Shen Huang aff005;  Chun-Wei Wang aff001
Působiště autorů: Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan aff001;  Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan aff002;  Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan aff003;  Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University, College of Medicine, Taipei, Taiwan aff004;  Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan aff005;  Department of Radiology, College of Medicine, National Taiwan University, Taipei, Taiwan aff006
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0225962

Souhrn

Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are limited. This study aimed to compare the treatment outcomes between definitive chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. Ninety-three N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT may achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Caution should be made to avoid overtreatment for this group of patients.

Klíčová slova:

Cancer chemotherapy – Cancer treatment – Head and neck cancers – Larynx – Neck – Surgical and invasive medical procedures – Surgical oncology – Oropharynx


Zdroje

1. Cohen E.E., Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al., Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol, 2014. 32(25): p. 2735–43. doi: 10.1200/JCO.2013.54.6309 25049329

2. Haddad R., O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol, 2013. 14(3): p. 257–64. doi: 10.1016/S1470-2045(13)70011-1 23414589

3. Mehanna H., Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, et al., PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med, 2016. 374(15): p. 1444–54. doi: 10.1056/NEJMoa1514493 27007578

4. Lorch J.H., Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al., Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol, 2011. 12(2): p. 153–9. doi: 10.1016/S1470-2045(10)70279-5 21233014

5. Huang S.H., O'Sullivan B, Xu W, Zhao H, Chen DD, Ringash J, et al., Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys, 2013. 87(5): p. 1078–85. doi: 10.1016/j.ijrobp.2013.08.049 24210079

6. Hamoir M., Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, et al., The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol, 2012. 48(3): p. 203–10. doi: 10.1016/j.oraloncology.2011.10.015 22104248

7. Spector M.E., Chinn SB, Bellile E, Gallagher KK, Ibrahim M, Vainshtein J, et al., Matted Nodes Predict Distant Metastasis in Advanced Stage III/IV Oropharyngeal Squamous Cell Carcinoma. Head Neck, 2016. 38(2): p. 184–90. doi: 10.1002/hed.23882 25251643

8. Adams G., Porceddu SV, Pryor DI, Panizza B, Foote M, Rowan A, et al., Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET—guided neck management policy. Head Neck, 2014. 36(8): p. 1200–6. doi: 10.1002/hed.23434 23893554

9. Igidbashian L., Fortin B, Guertin L, Soulieres D, Coulombe G, Belair M, et al., Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2010. 77(2): p. 414–20. doi: 10.1016/j.ijrobp.2009.05.034 19775825

10. Karakaya E., Yetmen O, Oksuz DC, Dyker KE, Coyle C, Sen M, et al., Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection. Oral Oncol, 2013. 49(1): p. 55–9. doi: 10.1016/j.oraloncology.2012.07.010 22858313

11. Zenga J., Haughey BH, Jackson RS, Adkins DR, Aranake-Chrisinger J, Bhatt N, et al., Outcomes of surgically treated human papillomavirus-related oropharyngeal squamous cell carcinoma with N3 disease. Laryngoscope, 2016.

12. Argiris, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, A., et al., Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol, 2003. 14(8): p. 1306–11. doi: 10.1093/annonc/mdg330 12881397

13. Corry J., Peters L, Fisher R, Macann A, Jackson M, McClure B, et al., N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck, 2008. 30(6): p. 737–42. doi: 10.1002/hed.20769 18286488

14. Jung J.H., Roh JL, Lee JH, Kim SB, Lee SW, Choi SH, et al., Prognostic factors in patients with head and neck squamous cell carcinoma with cN3 neck disease: a retrospective case-control study. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014. 117(2): p. 178–85. doi: 10.1016/j.oooo.2013.09.010 24268799

15. Ko H.C., Chen S, Wieland AM, Yu M, Baschnagel AM, Hartig GK, et al., Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head Neck, 2017. 39(11): p. 2159–2170. doi: 10.1002/hed.24881 28737019

16. Smyth J.K., Deal AM, Huang B, Weissler M, Zanation A, Shores C. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection. Laryngoscope, 2011. 121(9): p. 1881–7. doi: 10.1002/lary.21968 21997727

17. Jones A.S., Goodyear PW, Ghosh S, Husband D, Helliwell TR, Jones TM. Extensive neck node metastases (N3) in head and neck squamous carcinoma: is radical treatment warranted? Otolaryngol Head Neck Surg, 2011. 144(1): p. 29–35. doi: 10.1177/0194599810390191 21493383

18. Witek M.E., Wieland AM, Chen S, Kennedy TA, Hullett CR, Liang E, et al., Outcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease. Cancers Head Neck, 2017. 2.

19. Elicin O., Albrecht T, Haynes AG, Bojaxhiu B, Nisa L, Caversaccio M, et al., Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. Otolaryngol Head Neck Surg, 2016. 154(2): p. 300–8. doi: 10.1177/0194599815608370 26450749

20. Cacicedo J., Navarro A, Del Hoyo O, Gomez-Iturriaga A, Alongi F, Medina JA, et al., Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. Br J Radiol, 2016. 89(1067): p. 20160217. doi: 10.1259/bjr.20160217 27416996


Článek vyšel v časopise

PLOS One


2019 Číslo 12
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

KOST
Koncepce osteologické péče pro gynekology a praktické lékaře
nový kurz
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Svět praktické medicíny 5/2023 (znalostní test z časopisu)

Imunopatologie? … a co my s tím???
Autoři: doc. MUDr. Helena Lahoda Brodská, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#